british columbia registered: Live & Latest News Updates : Vimarsana.com

BioVaxys Technology Corp.: BIOVAXYS ANNOUNCES PROPOSED DEBT SETTLEMENT

VANCOUVER, B.C., July 5, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF) ("BioVaxys" or the "Company") announces that is proposing to settle an aggregate of

BIOVAXYS ANNOUNCES PROPOSED DEBT SETTLEMENT

/CNW/ - BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF) ("BioVaxys" or the "Company") announces that is proposing to settle an aggregate of...

BioVaxys Technology Corp.: BIOVAXYS ANNOUNCES APPOINTMENT TO BOARD OF DIRECTORS

VANCOUVER, BC, April 29, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that Mr. Anthony Dutton has been

BIOVAXYS ANNOUNCES APPOINTMENT TO BOARD OF DIRECTORS

/PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that Mr. Anthony Dutton has...

BIOVAXYS ANNOUNCES APPOINTMENT TO BOARD OF DIRECTORS

/PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that Mr. Anthony Dutton has...

BioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX-0918 Bioproduction

/PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that it has entered into an agreement...

BioVaxys Technology Corp.: BioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX-0918 Bioproduction

VANCOUVER, BC, April 25, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that it has entered into an agreement with

Stock Market | FinancialContent Business Page

BioVaxys Technology Corp.: BioVaxys Closes Final Tranche of Non-brokered Private Placement

VANCOUVER, BC, Feb. 28, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that it has closed

BIOVAXYS ANNOUNCES complete inhibition of ACE-2 binding activity of hapten-modified SARS-CoV-2 protein

/PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAX) ("BioVaxys" or "Company") announced today that studies on BVX-0320, its...